3种用药方案治疗急性脑梗死的成本-效果分析

目的:比较3种用药方案治疗急性脑梗死的经济学效果。方法:92例急性脑梗死住院患者按照不同药物治疗方案分为A、B、C组,A组给予丁苯酞软胶囊,B组给予苯磺酸氨氯地平片、阿司匹林肠溶片和胞磷胆碱胶囊,C组给予银杏叶片。治疗14d后观察疗效,并运用成本-效果法进行分析。结果:A、B、C组的显效率分别为78.57%、66.67%、48.39%,成本分别为8860.71、8107.45、7854.65元,成本-效果比分别为11277.47、12160.57、16231.97,A、B组相对于C组的增量成本-效果比分别为3333.53、1382.93。结论:从药物经济学角度分析,B组方案治疗急性脑梗死较佳。

Cost-effectiveness Analysis of Three Therapeutic Regimes for Acute Cerebral Infarction

OBJECTIVE： To compare the pharmacoeconomic effect of three therapeutic regimes for acute cerebral infarction （ACI）. METHODS： 92 cases of ACI were divided into group A, group B and group C according to therapeutic regimes. Group A was treated with Butylphthalide soft capsules, group B Amlodipine besylate tablets, Aspirin enteric-coated tablets and Citicoline sodium capsules, and group C Ginkgo tablets respectively. The curative efficacies were observed to analyze cost-effectiveness after 14 days of treatment. RESULTS： The effective rates of group A, group B and group C were 78.57%, 66.67% and 48.39%. The costs were 8 860.71 yuan, 8 107.45 yuan and 7 854.65 yuan. The cost-effectiveness ratios were 11 277.47, 12 160.57 and 16 231.97, respectively. The incremental cost-effectiveness ratios of group A and group B were 3 333.53 and 1 382.93, compared with group C. CONCLUSION： From the perspective of pharmacoeconomics, Group B is optimal in the treatment of ACI .